. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Kidney Int. 2015 May 6;88(3):622–632. doi: 10.1038/ki.2015.142

Table 3D.

Outcome: End Stage Renal Disease
	non-RH	cRH	uRH
Medication Usage (Yes vs No)	Hazard Ratio (95% CI)	Hazard Ratio (95% CI)	Hazard Ratio (95% CI)
ACEI	0.77 (0.73, 0.81)	0.80 (0.69, 0.94)	0.89 (0.79, 1.00)
ARB	0.92 (0.85, 1.00)	1.03 (0.88, 1.21)	1.05 (0.92, 1.19)
Thiazide Diuretic	0.62 (0.59, 0.66)	0.85 (0.74, 0.97)	0.72 (0.64, 0.80)
Loop Diuretic	1.71 (1.60, 1.83)	1.78 (1.55, 2.04)	1.55 (1.39, 1.72)
Beta Blockers	0.95 (0.90, 0.99)	1.05 (0.90, 1.22)	1.02 (0.92, 1.14)
Dihydropyridine CCB	1.46 (1.36, 1.57)	1.39 (1.24, 1.56)	1.53 (1.40, 1.69)
Non-Dihydropyridine CCB	1.40 (1.29, 1.53)	1.43 (1.22, 1.68)	1.30 (1.14, 1.49)
Alpha Agonist	1.55 (1.33, 1.80)	1.50 (1.32, 1.70)	1.50 (1.35, 1.67)
Mineralocorticoid Receptor Blocker	1.19 (1.00, 1.41)	0.75 (0.62, 0.89)	0.75 (0.59, 0.97)